HCM
NKTR icon

Harvey Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Harvey Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-333
Closed -$304K – 77
2018
Q3 		$304K Sell
333
-1,815
-84% -$1.55M 0.12% 67
2018
Q2 		$1.57M Sell
2,148
-2,084
-49% -$2.4M 0.62% 45
2018
Q1 		$6.74M Sell
4,232
-6,389
-60% -$8.23M 2.52% 12
2017
Q4 		$9.51M Sell
10,621
-8,526
-45% -$5.04M 3.45% 5
2017
Q3 		$6.89M Sell
19,147
-70
-0.4% -$21.9K 2.78% 13
2017
Q2 		$5.63M Buy
19,217
+214
+1% +$61.8K 2.42% 19
2017
Q1 		$6.69M Sell
19,003
-3,844
-17% -$864K 3.01% 12
2016
Q4 		$4.2M Sell
22,847
-2,636
-10% -$536K 1.96% 19
2016
Q3 		$6.57M Sell
25,483
-9,390
-27% -$2.42M 2.03% 13
2016
Q2 		$7.44M Sell
34,873
-1,954
-5% -$437K 3.73% 9
2016
Q1 		$7.59M Sell
36,827
-3,066
-8% -$589K 3.68% 10
2015
Q4 		$10.1M Sell
39,893
-4,707
-11% -$968K 3.98% 4
2015
Q3 		$7.33M Buy
44,600
+3,287
+8% +$581K 2.93% 12
2015
Q2 		$7.37M Buy
41,313
+20,393
+97% +$3.51M 2.49% 12
2015
Q1 		$3.45M Buy
20,920
+6,230
+42% +$1.28M 1.27% 29
2014
Q4 		$3.42M Sell
14,690
-93
-0.6% -$19.9K 1.31% 25
2014
Q3 		$2.68M Buy
14,783
+586
+4% +$112K 1.05% 31
2014
Q2 		$2.73M Buy
14,197
+5,504
+63% +$973K 0.98% 31
2014
Q1 		$1.58M Buy
+8,693
New +$1.72M 0.63% 37

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harvey Capital Management's NKTR Position: Q4 2018 in Review

Harvey Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 333 shares — an estimated $304K sold.

Harvey Capital Management first reported a position in NKTR in Q1 2014 and held it in 19 quarters. The position peaked at $10.1M in Q4 2015. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Harvey Capital Management reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Harvey Capital Management sold 333 Nektar Therapeutics shares in Q4 2018, an estimated $304K.
  • Harvey Capital Management first reported a position in Nektar Therapeutics in Q1 2014 and held it in 19 quarters.
  • Harvey Capital Management's Nektar Therapeutics position peaked at $10.1M in Q4 2015.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Harvey Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.